Natera, Inc. (NTRA) slumps 15% after earnings miss
Natera, Inc. (NTRA) slumps after reporting strong revenue growth but a much larger-than-expected quarterly EPS loss. Investors are weighing rising spending, a CEO transition, and whether the company can turn rapid oncology test growth into better earnings.
Natera, Inc. (NTRA) slumped sharply after hours after its Q3 report showed strong 34.1% revenue growth but a much wider-than-expected EPS loss of -$0.64 versus -$0.17 estimated. The selloff reflects investor concern over heavier SG&A and R&D spending, plus an immediate CEO transition, even as the company raised full-year revenue guidance and posted strong oncology test growth. For investors, the message is clear: the growth story remains intact, but the stock now depends on better earnings conversion and execution.
Natera, Inc. (NTRA) slumps 15.33% in extended-hours trading, with shares printed at $308 versus the prior close of $363.76. The sharp drop follows Q3 2026 results that showed strong revenue growth but a much larger-than-expected EPS loss, while regular-session trading will confirm whether the decline holds.
Key Takeaways
The clearest catalyst is Natera's November 5 Q3 earnings report, which showed EPS of -$0.64 versus a -$0.17 estimate.
Revenue rose 34.1% to $794.0 million, and Natera raised its 2026 revenue guidance midpoint by $140 million.
Higher SG&A and R&D guidance, plus an immediate CEO transition, gave investors reasons to question near-term earnings leverage.
The business still shows strong oncology momentum, but the stock now needs growth, spending discipline, and leadership execution to improve together.
The November 5 earnings report is the primary reason NTRA is down sharply after hours. Natera reported Q3 revenue of $794.0 million, up 34.1% from $592.2 million a year earlier. However, earnings data showed an EPS loss of $0.64 against an estimated loss of $0.17. That produced a negative surprise of 276.5%.
That split explains the unusual reaction. Revenue and testing activity were strong, yet the bottom line missed by a wide margin. The also showed gross margin of 64.7%. Management reported that non-GAAP gross margin, excluding revenue true-ups, increased 137 basis points sequentially. Still, investors focused on the earnings loss and the cost required to sustain the company's growth.
NTRA had already fallen 6.97% during the regular session to $363.76. The extended-hours print at $308 adds a second wave of selling. Elevated volume of roughly 3.1 million to 3.2 million shares on November 5 shows that the reaction was more than a thinly traded price fluctuation.
Natera's Revenue Growth Is Strong, but EPS Pressure Matters
Natera's operating metrics support a durable growth story. The company processed about 1.093 million tests in Q3, up 22.3% year over year. Oncology tests increased 60.9% to about 339,500. Clinical MRD oncology tests reached roughly 316,000, compared with 202,000 in Q3 2025.
Signatera remains central to that momentum. The personalized cancer test supports minimal residual disease monitoring, recurrence tracking, and treatment response analysis. Natera also offers Latitude, Altera, and Empower across colorectal cancer, genomic profiling, and hereditary cancer screening. The expanding test base gives the company a competitive position in molecular diagnostics, especially in oncology.
However, growth has not removed the need for operating discipline. Natera guided to SG&A of $1.225 billion to $1.300 billion and R&D of $825 million to $925 million. The company cited one-time expenses and faster Signatera marketing investments. In plain English, Natera is spending heavily to widen its lead. That can support future revenue, but it also limits the immediate benefit of higher sales on earnings.
The company raised full-year 2026 revenue guidance from $2.850 billion to $2.910 billion to a new range of $3.005 billion to $3.035 billion. Management linked the increase to volume growth, conservative average selling prices, and strong oncology contribution. Therefore, the selloff does not reflect a collapse in the revenue outlook. It reflects a market that wanted stronger earnings conversion from that growth.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
CEO Transition Adds Risk to NTRA's High-Expectation Story
Natera also announced a leadership change on November 5. Solomon Moshkevich became CEO and joined the board effective immediately, while Steve Chapman stepped down from the CEO role. The timing matters because the leadership change arrived beside an earnings loss, higher expense guidance, and a large stock decline.
The transition does not erase Natera's commercial progress. It does increase the execution burden. The company has tied its long-term plan to a $6 billion revenue target for 2029 while continuing to invest in Signatera and other testing platforms. Investors now have to value that plan alongside a new CEO and a recent EPS miss.
The broader market also added pressure. Coverage of November 5 described a broad selloff in growth and AI-related names. Natera is a healthcare diagnostics company, but its 1.515 beta and $52.43 billion market capitalization give it the profile of a growth stock during risk-off trading. That backdrop likely amplified the company-specific earnings reaction.
What NTRA Investors Should Do After the 15.33% Drop
The practical takeaway is to separate business momentum from stock momentum. Revenue growth of 34.1%, oncology test growth of 60.9%, and a $140 million guidance increase support the operating case. The -$0.64 EPS result, higher investment levels, and immediate CEO change explain why the market applied pressure anyway.
Investors assessing NTRA should focus on whether the higher test volume begins to produce better earnings, not only higher revenue. The next regular-session reaction also matters because the $308 extended-hours print is below the prior close, while the analyst consensus target stands at $386 and the median target at $407.50. Those targets range from $245 to $500, showing meaningful disagreement even before this move.
A disciplined approach avoids treating the drop as either an automatic bargain or proof that the growth story is broken. Strong oncology demand supports the long-term case, while the earnings miss and spending plan create a real test for the new leadership team. The balance between those facts will shape NTRA's next phase.
Bottom Line on Why Natera Stock Is Down After Hours
NTRA's after-hours slump is best explained by a sharp EPS miss, higher planned spending, and an immediate CEO transition, not by weak revenue demand. Natera still delivered strong testing growth and raised 2026 revenue guidance, but the stock now needs those gains to translate into improved earnings and steady execution.
NTRA is down because its Q3 earnings missed expectations badly, with EPS at -$0.64 versus a -$0.17 estimate. Investors also reacted to higher spending guidance and an immediate CEO change.
+Should I buy NTRA stock now?
The drop may interest long-term growth investors, but the stock still faces earnings and execution risk. A better approach is to wait for proof that revenue growth is translating into improved profitability.
+Did Natera's revenue actually grow?
Yes. Natera reported Q3 revenue of $794.0 million, up 34.1% year over year, and also raised its 2026 revenue guidance. The market is reacting to the earnings miss, not weak sales.
+What does the CEO change mean for NTRA investors?
The leadership transition adds uncertainty at a time when investors already want better earnings discipline. It does not change the growth story, but it raises the execution bar for the new CEO.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on NTRA?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
